Leflunomide for Idiopathic Pulmonary Hemosiderosis in Children
Leflunomide is Safe and Effective for the Induction and Maintenance of Idiopathic Pulmonary Hemosiderosis Remission
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
34 participants
Jun 1, 2023
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to compare Leflunomide in Idiopathic pulmonary hemosiderosis. The main questions it aims to answer are: * The efficacy and safety of Leflunomide in Idiopathic pulmonary hemosiderosis * The mechanism of leflunomide in treating Idiopathic pulmonary hemosiderosis Participants will be treated with leflunomide plus stroid. A comparison group: Researchers will compare the control group treated with stroid to see if the efficacy of Leflunomide would be better than control group.
Eligibility
Inclusion Criteria3
- Age range from 6 months to 18 years old;
- Diagnose as IPH;
- Parents or guardians agree to treatment and sign a written informed consent form.
Exclusion Criteria6
- Individuals who are allergic to any ingredients used in leflunomide tablets;
- Complicated with serious basic diseases (such as systemic malignant diseases, heart failure, liver and kidney failure, immune deficiency, serious infectious diseases, Lung transplantation or other patients with immediate surgical indications);
- Patients with other lung diseases;
- Have a history of abnormal coagulation or abnormal coagulation function in the past;
- Clinical trial participants who have previously participated in the treatment of flumiphene;
- Other situations where the researcher deems it inappropriate to participate in the study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Leflunomide+Glucocorticoids treatment Group
Steroid Treatment
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05937191